Vaccination strategies in tauopathies and synucleinopathies

Journal of Neurochemistry

Volumn 143, Issue 5, 2017, Pages 467-488

  Braczynski, Anne K ^a   Schulz, Jörg B ^a,b   Bach, Jan Philipp ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

active immunization; Alzheimer disease; naturally occurring autoantibodies; neurodegenerative disorders; Parkinson disease; passive immunization

Indexed keywords

ABBV 8E12; ABVAC 40; ACI 24; ADUCANUMAB; ALPHA SYNUCLEIN; ALUMINUM HYDROXIDE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BAPINEUZUMAB; BIIB 054; C2N E812; CRENEZUMAB; DNA VACCINE; ELN 115727; FLORBETAPIR F 18; FREUND ADJUVANT; GANTENERUMAB; GN 29632; HUMAN IMMUNOGLOBULIN; KEYHOLE LIMPET HEMOCYANIN; LU AF20513; MEDI 1814; MONOCLONAL ANTIBODY; PERTUSSIS TOXIN; PF 05236806; PLACEBO; PONEZUMAB; PRX 002; RO 4909832; SOLANEZUMAB; SYN 303; TAU PROTEIN; UB 311; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ALZHEIMER DISEASE; ASEPTIC MENINGITIS; BLOOD BRAIN BARRIER; DEMENTIA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FRONTOTEMPORAL DEMENTIA; HUMAN; IMMUNOGENICITY; LEWY BODY; MENINGOENCEPHALITIS; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSON DISEASE; PASSIVE IMMUNIZATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; SYNUCLEINOPATHY; TAUOPATHY; VACCINATION; ANIMAL; IMMUNOLOGY; METABOLISM; PROCEDURES;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; PARKINSON DISEASE; TAUOPATHIES; VACCINATION;

EID: 85031413201     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.14207     Document Type: Review

References (142)

1. Abeliovich A. and Gitler A. D. (2016) Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature 539, 207–216.
2. d'Abramo C., Acker C. M., Jimenez H. T. and Davies P. (2013) Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS ONE 8, e62402.
3. Albus A., Bach J.-P., Roettger Y., Dodel R. and Gold M. (2014) Characterization of the epitope specificity of naturally occurring autoantibodies against α-synuclein, β-amyloid and prion protein [abstract]. Mov. Disord. 29(Suppl 1), 3.
4. Allen B., Ingram E., Takao M. et al. (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340–9351.
5. Alonso A. C., Grundke-Iqbal I. and Iqbal K. (1996) Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 2, 783–787.
6. Andreasen N., Simeoni M., Ostlund H. et al. (2015) First administration of the Fc-attenuated anti-beta amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. PLoS ONE 10, e0098153.
7. Armstrong R. A., Lantos P. L. and Cairns N. J. (2007) Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical regions of eight cases. J. Neural. Transm (Vienna) 114, 1569–1577.
8. Asuni A. A., Boutajangout A., Quartermain D. and Sigurdsson E. M. (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115–9129.
9. Bach J. P. and Dodel R. (2012) Naturally occurring autoantibodies against beta-Amyloid. Adv. Exp. Med. Biol. 750, 91–99.
10. Bae E. J., Lee H. J., Rockenstein E., Ho D. H., Park E. B., Yang N. Y., Desplats P., Masliah E. and Lee S. J. (2012) Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32, 13454–13469.
11. Bateman R. J., Xiong C., Benzinger T. L. et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795–804.
12. Berg D., Postuma R. B., Adler C. H. et al. (2015) MDS research criteria for prodromal Parkinson's disease. Mov. Disord. 30, 1600–1611.
13. Bergstrom A. L., Kallunki P. and Fog K. (2016) Development of passive immunotherapies for synucleinopathies. Mov. Disord. 31, 203–213.
14. Besong-Agbo D., Wolf E., Jessen F. et al. (2013) Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80, 169–175.
15. Bettens K., Sleegers K. and Van Broeckhoven C. (2013) Genetic insights in Alzheimer's disease. Lancet Neurol. 12, 92–104.
16. Blanz J. and Saftig P. (2016) Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance. J. Neurochem. 139(Suppl 1), 198–215.
17. Bohrmann B., Baumann K., Benz J. et al. (2012) Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J. Alzheimers Dis. 28, 49–69.
18. Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O. and Rosenmann H. (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 224, 472–485.
19. Boutajangout A., Quartermain D. and Sigurdsson E. M. (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30, 16559–16566.
20. Braak H., Del Tredici K., Rub U., de Vos R. A., Jansen Steur E. N. and Braak E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211.
21. Braak H., de Vos R. A., Bohl J. and Del Tredici K. (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396, 67–72.
22. Castillo-Carranza D. L., Gerson J. E., Sengupta U., Guerrero-Munoz M. J., Lasagna-Reeves C. A. and Kayed R. (2014a) Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J. Alzheimers Dis. 40(Suppl 1), S97–S111.
23. Castillo-Carranza D. L., Sengupta U., Guerrero-Munoz M. J. et al. (2014b) Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 34, 4260–4272.
24. Chai X., Wu S., Murray T. K. et al. (2011) Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J. Biol. Chem. 286, 34457–34467.
25. Chen Z., Yang Y., Yang X., Zhou C., Li F., Lei P., Zhong L., Jin X. and Peng G. (2013) Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease. Neurol. Sci. 34, 1559–1570.
26. Collin L., Bohrmann B., Gopfert U., Oroszlan-Szovik K., Ozmen L. and Gruninger F. (2014) Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain 137, 2834–2846.
27. Colonna M. and Wang Y. (2016) TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat. Rev. Neurosci. 17, 201–207.
28. Danzer K. M., Haasen D., Karow A. R., Moussaud S., Habeck M., Giese A., Kretzschmar H., Hengerer B. and Kostka M. (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27, 9220–9232.
29. Davtyan H., Ghochikyan A., Petrushina I. et al. (2013) Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J. Neurosci. 33, 4923–4934.
30. Dehay B., Bourdenx M., Gorry P. et al. (2015) Targeting alpha-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 14, 855–866.
31. DeMattos R. B., Bales K. R., Cummins D. J., Paul S. M. and Holtzman D. M. (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264–2267.
32. Demattos R. B., Lu J., Tang Y. et al. (2012) A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron 76, 908–920.
33. Dodel R., Hampel H., Depboylu C. et al. (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann. Neurol. 52, 253–256.
34. Dodel R. C., Du Y., Depboylu C. et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472–1474.
35. Dodel R., Neff F., Noelker C., Pul R., Du Y., Bacher M. and Oertel W. (2010) Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 70, 513–528.
36. Dodel R., Balakrishnan K., Keyvani K. et al. (2011) Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J. Neurosci. 31, 5847–5854.
37. Dodel R., Rominger A., Bartenstein P. et al. (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 12, 233–243.
38. Doody R. S., Thomas R. G., Farlow M. et al. (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311–321.
39. Doppler K., Jentschke H. M., Schulmeyer L. et al. (2017) Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. Acta Neuropathol. 4, 535–545.
40. Farlow M. R., Andreasen N., Riviere M. E., Vostiar I., Vitaliti A., Sovago J., Caputo A., Winblad B. and Graf A. (2015) Long-term treatment with active Abeta immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res. Ther. 7, 23.
41. Ferrer I. (2011) Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis. 2011, 708404.
42. Games D., Valera E., Spencer B. et al. (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J. Neurosci. 34, 9441–9454.
43. Gaskin F., Finley J., Fang Q., Xu S. and Fu S. M. (1993) Human antibodies reactive with beta-amyloid protein in Alzheimer's disease. J. Exp. Med. 177, 1181–1186.
44. George J. M. (2002) The synucleins. Genome Biol. 3, 3002.
45. Ghochikyan A., Petrushina I., Davtyan H., Hovakimyan A., Saing T., Davtyan A., Cribbs D. H. and Agadjanyan M. G. (2014) Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human alpha-synuclein: feasibility study. Neurosci. Lett. 560, 86–91.
46. Giasson B. I., Murray I. V., Trojanowski J. Q. and Lee V. M. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380–2386.
47. Gilman S., Wenning G. K., Low P. A. et al. (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670–676.
48. Goedert M. (2004) Tau protein and neurodegeneration. Semin. Cell Dev. Biol. 15, 45–49.
49. Goedert M., Spillantini M. G., Jakes R., Rutherford D. and Crowther R. A. (1989a) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519–526.
50. Goedert M., Spillantini M. G., Potier M. C., Ulrich J. and Crowther R. A. (1989b) Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 8, 393–399.
51. Gold M. and El Khoury J. (2015) beta-amyloid, microglia, and the inflammasome in Alzheimer's disease. Semin. Immunopathol. 37, 607–611.
52. Gold M., Mengel D., Roskam S., Dodel R. and Bach J. P. (2013) Mechanisms of action of naturally occurring antibodies against beta-amyloid on microglia. J. Neuroinflammation 10, 5.
53. Goodwin K., Viboud C. and Simonsen L. (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24, 1159–1169.
54. Guerreiro R., Wojtas A., Bras J. et al. (2013) TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117–127.
55. Hashimoto M., Rockenstein E., Crews L. and Masliah E. (2003) Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med. 4, 21–36.
56. Heneka M. T., Kummer M. P., Stutz A. et al. (2013) NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493, 674–678.
57. Heneka M. T., Carson M. J., El Khoury J. et al. (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14, 388–405.
58. Hirtz D., Thurman D. J., Gwinn-Hardy K., Mohamed M., Chaudhuri A. R. and Zalutsky R. (2007) How common are the “common” neurologic disorders? Neurology 68, 326–337.
59. Holmqvist S., Chutna O., Bousset L. et al. (2014) Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 128, 805–820.
60. Istrin G., Bosis E. and Solomon B. (2006) Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J. Neurosci. Res. 84, 434–443.
61. Ittner A., Bertz J., Suh L. S., Stevens C. H., Gotz J. and Ittner L. M. (2015) Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J. Neurochem. 132, 135–145.
62. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H. A., Kittel A. and Saitoh T. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467–475.
63. Jang A., Lee H. J., Suk J. E., Jung J. W., Kim K. P. and Lee S. J. (2010) Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J. Neurochem. 113, 1263–1274.
64. Jeganathan S., Hascher A., Chinnathambi S., Biernat J., Mandelkow E. M. and Mandelkow E. (2008) Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J. Biol. Chem. 283, 32066–32076.
65. Kalia L. V., Kalia S. K. and Lang A. E. (2015) Disease-modifying strategies for Parkinson's disease. Mov. Disord. 30, 1442–1450.
66. Karantzoulis S. and Galvin J. E. (2011) Distinguishing Alzheimer's disease from other major forms of dementia. Expert Rev. Neurother. 11, 1579–1591.
67. Kasaian M. T. and Casali P. (1993) Autoimmunity-prone B-1 (CD5 B) cells, natural antibodies and self recognition. Autoimmunity 15, 315–329.
68. Kellner A., Matschke J., Bernreuther C., Moch H., Ferrer I. and Glatzel M. (2009) Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann. Neurol. 65, 24–31.
69. Kfoury N., Holmes B. B., Jiang H., Holtzman D. M. and Diamond M. I. (2012) Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 287, 19440–19451.
70. Kim C., Ho D. H., Suk J. E. et al. (2013) Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562.
71. Klingelhoefer L. and Reichmann H. (2015) Pathogenesis of Parkinson disease–the gut-brain axis and environmental factors. Nat. Rev. Neurol. 11, 625–636.
72. Kontsekova E., Zilka N., Kovacech B., Novak P. and Novak M. (2014) First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res. Ther. 6, 44.
73. Kronimus Y., Albus A., Balzer-Geldsetzer M. et al. (2016) Naturally occurring autoantibodies against tau protein are reduced in Parkinson's disease dementia. PLoS ONE 11, e0164953.
74. La Porte S. L., Bollini S. S., Lanz T. A. et al. (2012) Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J. Mol. Biol. 421, 525–536.
75. Lannfelt L., Moller C., Basun H., Osswald G., Sehlin D., Satlin A., Logovinsky V. and Gellerfors P. (2014) Perspectives on future Alzheimer therapies: amyloid-beta protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res. Ther. 6, 16.
76. Lee J. S. and Lee S. J. (2016) Mechanism of anti-alpha-synuclein immunotherapy. J. Mov. Disord. 9, 14–19.
77. Lee V. M. and Trojanowski J. Q. (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 33–38.
78. Lee H. J., Suk J. E., Bae E. J. and Lee S. J. (2008) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem. Biophys. Res. Commun. 372, 423–428.
79. Lilly. (2016) Lilly announces top-line results of Solanezumab phase 3 clinical trial. https://investor.lilly.com/releasedetail.cfm?ReleaseID=1000871.
80. Lindstrom V., Fagerqvist T., Nordstrom E. et al. (2014) Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice. Neurobiol. Dis. 69, 134–143.
81. Loeffler D. A. (2013) Intravenous immunoglobulin and Alzheimer's disease: what now? J. Neuroinflammation 10, 70.
82. Loy C. T., Schofield P. R., Turner A. M. and Kwok J. B. (2014) Genetics of dementia. Lancet 383, 828–840.
83. Luk K. C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J. Q. and Lee V. M. (2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953.
84. Mandelkow E. M. and Mandelkow E. (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect Med. 2, a006247.
85. Mandelkow E., vonBergen M., Biernat J. and Mandelkow E. M. (2007) Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol. 17, 83–90.
86. Mandler M., Valera E., Rockenstein E. et al. (2014) Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol. 127, 861–879.
87. Mandler M., Valera E., Rockenstein E. et al. (2015) Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol. Neurodegener. 10, 10.
88. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. and Mucke L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265–1269.
89. Masliah E., Rockenstein E., Adame A. et al. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857–868.
90. Masliah E., Rockenstein E., Mante M. et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6, e19338.
91. McEwan W. A., Falcon B., Vaysburd M., Clift D., Oblak A. L., Ghetti B., Goedert M. and James L. C. (2017) Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc. Natl Acad. Sci. USA 114, 574–579.
92. McGeer P. L. and McGeer E. G. (2015) Targeting microglia for the treatment of Alzheimer's disease. Expert Opin. Ther. Targets 19, 497–506.
93. Melki R. (2017) How the shapes of seeds can influence pathology. Neurobiol. Dis. 17, pii: S0969-9961(17)30060-8.
94. Mengel D., Roskam S., Neff F. et al. (2013) Naturally occurring autoantibodies interfere with beta-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment. Transl. Psychiat. 3, e236.
95. Migdalska-Richards A. and Schapira A. H. (2016) The relationship between glucocerebrosidase mutations and Parkinson disease. J. Neurochem. 139(Suppl 1), 77–90.
96. Novak P., Schmidt R., Kontsekova E. et al. (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 16, 123–134.
97. Oertel W. and Schulz J. B. (2016) Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J. Neurochem. 139(Suppl 1), 325–337.
98. O'Nuallain B., Acero L., Williams A. D., Koeppen H. P., Weber A., Schwarz H. P., Wall J. S., Weiss D. T. and Solomon A. (2008) Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 47, 12254–12256.
99. Pan-Montojo F., Schwarz M., Winkler C. et al. (2012) Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci. Rep. 2, 898.
100. Parkinson J. (1817) An Essay on the Shaking Palsy. pp. 223–236. Neely and Jones, Sherwood, London.
101. Peelaerts W., Bousset L., Van der Perren A., Moskalyuk A., Pulizzi R., Giugliano M., Van den Haute C., Melki R. and Baekelandt V. (2015) alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340–344.
102. Querfurth H. W. and LaFerla F. M. (2010) Alzheimer's disease. N. Engl. J. Med. 362, 329–344.
103. Relkin N. R., Szabo P., Adamiak B. et al. (2009) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30, 1728–1736.
104. Riedl L., Mackenzie I. R., Forstl H., Kurz A. and Diehl-Schmid J. (2014) Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr. Dis. Treat. 10, 297–310.
105. Riek R. and Eisenberg D. S. (2016) The activities of amyloids from a structural perspective. Nature 539, 227–235.
106. Robinson S. R., Bishop G. M., Lee H. G. and Munch G. (2004) Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol. Aging 25, 609–615.
107. Romero-Ramos M., von Euler Chelpin M. and Sanchez-Guajardo V. (2014) Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance? Hum. Vaccin. Immunother. 10, 852–867.
108. Rosenmann H., Grigoriadis N., Karussis D., Boimel M., Touloumi O., Ovadia H. and Abramsky O. (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 63, 1459–1467.
109. Rozenstein-Tsalkovich L., Grigoriadis N., Lourbopoulos A., Nousiopoulou E., Kassis I., Abramsky O., Karussis D. and Rosenmann H. (2013) Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp. Neurol. 248, 451–456.
110. Ryan J. M. and Grundman M. (2009) Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J. Alzheimers Dis. 17, 243.
111. Salloway S., Sperling R., Gilman S. et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061–2070.
112. Salloway S., Sperling R., Fox N. C. et al. (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 322–333.
113. Sanchez-Guajardo V., Tentillier N. and Romero-Ramos M. (2015) The relation between alpha-synuclein and microglia in Parkinson's disease: recent developments. Neuroscience 302, 47–58.
114. Sanders D. W., Kaufman S. K., DeVos S. L. et al. (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271–1288.
115. Sarkar C., Basu B., Chakroborty D., Dasgupta P. S. and Basu S. (2010) The immunoregulatory role of dopamine: an update. Brain Behav. Immun. 24, 525–528.
116. Scheltens P., Blennow K., Breteler M. M., de Strooper B., Frisoni G. B., Salloway S. and Van der Flier W. M. (2016) Alzheimer's disease. Lancet 388, 505–517.
117. Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177.
118. Schenk D. B., Koller M., Ness D. K. et al. (2017) First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov. Disord. 32, 211–218.
119. Schneeberger A., Tierney L. and Mandler M. (2016) Active immunization therapies for Parkinson's disease and multiple system atrophy. Mov. Disord. 31, 214–224.
120. Selenica M. L., Davtyan H., Housley S. B. et al. (2014) Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J. Neuroinflammation 11, 152.
121. Sevigny J., Chiao P., Bussiere T. et al. (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 537, 50–56.
122. Shahaduzzaman M., Nash K., Hudson C. et al. (2015) Anti-human alpha-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-alpha-synuclein rat model of Parkinson's disease. PLoS ONE 10, e0116841.
123. Shannon K. M., Keshavarzian A., Mutlu E., Dodiya H. B., Daian D., Jaglin J. A. and Kordower J. H. (2012) Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov. Disord. 27, 709–715.
124. Sigurdsson E. M. (2016) Tau Immunotherapy. Neurodegener. Dis. 16, 34–38.
125. Sperling R., Salloway S., Brooks D. J. et al. (2012) Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11, 241–249.
126. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839–840.
127. Stopschinski B. E. and Diamond M. I. (2017) The prion model for progression and diversity of neurodegenerative diseases. Lancet Neurol. 16, 323–332.
128. Svensson E., Horvath-Puho E., Thomsen R. W., Djurhuus J. C., Pedersen L., Borghammer P. and Sorensen H. T. (2015) Vagotomy and subsequent risk of Parkinson's disease. Ann. Neurol. 78, 522–529.
129. Tabira T. (2010) Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J. Exp. Med. 220, 95–106.
130. Theunis C., Crespo-Biel N., Gafner V. et al. (2013) Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS ONE 8, e72301.
131. Tran H. T., Chung C. H., Iba M., Zhang B., Trojanowski J. Q., Luk K. C. and Lee V. M. (2014) Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep. 7, 2054–2065.
132. Trojanowski J. Q., Vandeerstichele H., Korecka M. et al. (2010) Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 6, 230–238.
133. Ugen K. E., Lin X., Bai G., Liang Z., Cai J., Li K., Song S., Cao C. and Sanchez-Ramos J. (2015) Evaluation of an alpha synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson disease. Hum. Vaccin. Immunother. 11, 922–930.
134. Valera E., Spencer B. and Masliah E. (2016) Immunotherapeutic approaches targeting amyloid-beta, alpha-synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics 13, 179–189.
135. Wang C. Y., Finstad C. L., Walfield A. M. et al. (2007) Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine 25, 3041–3052.
136. Weihofen A., Patel H., Huy C. et al. (2016) Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo [abstract]. Movement Disorders, Vol. 31(suppl 2). http://www.mdsabstracts.org/abstract/human-derived-synuclein-antibody-biib054-binds-pathologic-forms-of-synuclein-and-attenuates-transmission-of-synuclein-in-vitro-and-in-vivo/. Accessed September 26, 2017.
137. Wesley J. D., Whitmore J., Trager J. and Sheikh N. (2012) An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer. Hum. Vaccin. Immunother. 8, 520–527.
138. Wimo A., Jonsson L., Bond J., Prince M. and Winblad B. (2013) The worldwide economic impact of dementia 2010. Alzheimers Dement. 9, e13.
139. Winner B., Jappelli R., Maji S. K. et al. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 4194–4199.
140. Wisniewski T. and Goni F. (2015) Immunotherapeutic approaches for Alzheimer's disease. Neuron 85, 1162–1176.
141. Yan Y., Jiang W., Liu L., Wang X., Ding C., Tian Z. and Zhou R. (2015) Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160, 62–73.
142. Yanamandra K., Kfoury N., Jiang H., Mahan T. E., Ma S., Maloney S. E., Wozniak D. F., Diamond M. I. and Holtzman D. M. (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402–414.